Standard complete blood count to predict long‐term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study
Guillemaud M, Hanin A, Riviello J, Chavez M, Batra A, Berry M, Bisulli F, Castillo‐Pinto C, Cobos‐Hernandez C, Demeret S, Eschbach K, Farias‐Moeller R, Fields M, Gaspard N, Gerard E, Gofton T, Gopaul M, Gruen M, Jimenez A, Kazazian K, Kim M, Mansour M, Marcuse L, Marois C, Morales M, Muccioli L, Pasini E, Pham M, Rosas S, Struck A, Torcida N, Wainwright M, Yoo J, Muscal E, Navarro V, Hirsch L, Lai Y. Standard complete blood count to predict long‐term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study. Epilepsia 2025 DOI: 10.1111/epi.18605.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeMonocyte-to-lymphocyte ratioNeutrophil-to-lymphocyte ratioComplete blood countNew-onset refractory status epilepticusSecond-line immunotherapyUnfavorable outcomeBlood countComplete blood count levelsHigh red cell distribution widthEpilepsy syndromesTreatment phaseFirst-line immunotherapyInitiation of immunotherapyRed cell distribution widthRefractory status epilepticusComplete blood count dataCell distribution widthLong-term outcomesIntensive care unitSubtypes of leukocytesLeave-one-patient-outMulticenter studyStatus epilepticusImmunotherapyClinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Nie Y, Wurtz A, Li F, Schalper K, Duffield E, Rowen E, Gerrish H, Chiang A, Goldberg S, Wilson F, Kim S, Grant M, Sabbath K, Talsania A, Lasala J, Russo A, Politi K, Herbst R, Gettinger S. Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2025, 43: 8544-8544. DOI: 10.1200/jco.2025.43.16_suppl.8544.Peer-Reviewed Original ResearchMetastatic non-small cell lung cancerNon-small cell lung cancerMonocyte-to-lymphocyte ratioAbsolute lymphocyte countPre-treatment absolute lymphocyte countResponse to immunotherapyCell lung cancerExceptional respondersLiver metastasesImmunotherapy responseAdvanced non-small cell lung cancerLung cancerTumor PD-L1 expressionPresence of brain metastasesInfluence immunotherapy responsivenessPD-L1 expressionSubsets of patientsTumor microenvironment analysisYale Cancer CenterTumor tissue analysisIRB-approved protocolLong-term survivalConcurrent chemotherapyBrain metastasesClinicopathological predictors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply